<DOC>
	<DOCNO>NCT00119392</DOCNO>
	<brief_summary>Monoclonal antibody , yttrium Y 90 ibritumomab tiuxetan , block find cancer cell either kill carry cancer-killing substance without harm normal cell . Giving monoclonal antibody , low dos chemotherapy , fludarabine phosphate , low dose total-body radiation therapy donor peripheral stem cell transplant help stop growth cancer cell also stop patient 's immune system reject donor 's stem cell . The donated stem cell may replace patient 's immune cell help destroy remain cancer cell ( graft-versus-tumor effect ) . Sometimes transplanted cell donor also make immune response body 's normal cell . Giving cyclosporine mycophenolate mofetil transplant may stop happen</brief_summary>
	<brief_title>Yttrium Y 90 Ibritumomab Tiuxetan , Fludarabine , Radiation Therapy , Donor Stem Cell Transplant Treating Patients With Relapsed Refractory Non-Hodgkin 's Lymphoma</brief_title>
	<detailed_description>PRIMARY OBJECTIVES : I . To assess feasibility , safety , potential efficacy treat patient B-Cell non-Hodgkin lymphoma ( NHL ) 90Y-ibritumomab tiuxetan , combine HLA-matched related unrelated donor hematopoietic cell transplantation . OUTLINE : Patients receive rituximab intravenously ( IV ) follow , 4 hour later , indium In 111 ibritumomab tiuxetan ( image ) IV 10 minute day -21 . Patients undergo gamma camera image day -19 . Patients receive rituximab IV follow , 4 hour later , yttrium Y 90 ibritumomab tiuxetan IV 10 minute day -14 . Patients also receive fludarabine phosphate IV 30-60 minute day -7 -5 undergo low-dose total-body irradiation ( TBI ) day 0 . After TBI , patient undergo allogeneic peripheral blood stem cell transplantation ( PBSCT ) day 0 . Patients undergo PBSCT relate donor receive oral cyclosporine twice daily day -3 56 followed taper day 180 absence graft-versus-host disease ( GVHD ) . These patient also receive oral mycophenolate mofetil twice daily day 0 27 . Patients undergo PBSCT unrelated donor receive oral cyclosporine twice daily day -3 100 follow taper 11 week absence GVHD . These patient also receive oral mycophenolate mofetil three time daily day 0 40 follow taper day 96 . After completion study treatment , patient follow 1 , 3 , 6 , 12 month , annually thereafter .</detailed_description>
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Lymphoma , Follicular</mesh_term>
	<mesh_term>Lymphoma , Non-Hodgkin</mesh_term>
	<mesh_term>Leukemia , Lymphoid</mesh_term>
	<mesh_term>Leukemia , Lymphocytic , Chronic , B-Cell</mesh_term>
	<mesh_term>Lymphoma , Large B-Cell , Diffuse</mesh_term>
	<mesh_term>Precursor Cell Lymphoblastic Leukemia-Lymphoma</mesh_term>
	<mesh_term>Burkitt Lymphoma</mesh_term>
	<mesh_term>Lymphoma , Large-Cell , Immunoblastic</mesh_term>
	<mesh_term>Plasmablastic Lymphoma</mesh_term>
	<mesh_term>Lymphoma , B-Cell</mesh_term>
	<mesh_term>Lymphoma , Mantle-Cell</mesh_term>
	<mesh_term>Lymphoma , B-Cell , Marginal Zone</mesh_term>
	<mesh_term>Waldenstrom Macroglobulinemia</mesh_term>
	<mesh_term>Lymphomatoid Granulomatosis</mesh_term>
	<mesh_term>Lymphoma , Extranodal NK-T-Cell</mesh_term>
	<mesh_term>Fludarabine</mesh_term>
	<mesh_term>Fludarabine phosphate</mesh_term>
	<mesh_term>Rituximab</mesh_term>
	<mesh_term>Mycophenolic Acid</mesh_term>
	<mesh_term>Antibodies</mesh_term>
	<mesh_term>Antibodies , Monoclonal</mesh_term>
	<mesh_term>Mycophenolate mofetil</mesh_term>
	<mesh_term>Cyclosporins</mesh_term>
	<mesh_term>Cyclosporine</mesh_term>
	<mesh_term>Vidarabine</mesh_term>
	<criteria>Patients must histologically confirm diagnosis lymphoid malignancy express cluster differentiation ( CD ) 20 antigen fail least one prior standard systemic therapy Patients must evidence persistent lymphoma physical examination , radiographic study , bone marrow evaluation , flow cytometry , polymerase chain reaction ( PCR ) Creatinine &lt; 2.0 Bilirubin &lt; 1.5 mg/dL Patients must expect survival &gt; 60 day must free major infection include human immunodeficiency virus ( HIV ) Patients must HLAidentical relate unrelated donor DONOR : Donor eligibility include HLAmatched relative HLA match , unrelated volunteer donor ; relate donor match molecular method intermediate resolution level HLAA , B , C , DRB1 accord FHCRC Standard Practice Guidelines allele level DQB1 ; unrelated donor identify use match criterion follow FHCRC Standard Practice Guidelines limit study eligible donor allele match HLAA , B , C , DRB1 , DQB1 ( Grade1 ) , accept one allele mismatch per Standard Practice Grade 2.1 HLAA , B , C Donor must consent granulocyte colonystimulating factor ( GCSF ) ( filgrastim ) administration leukapheresis Donor must adequate vein leukapheresis agree placement central venous catheter ( femoral , subclavian ) Systemic antilymphoma therapy give previous 30 day Patients experienced progressive disease within 3 month prior Bexxar Zevalin Inability understand give inform consent Central nervous system lymphoma Pregnancy Fertile men woman unwilling use contraceptive technique 12 month follow treatment Southwest Oncology Group ( SWOG ) /Eastern Cooperative Oncology Group ( ECOG ) performance score &gt; 2 Eligible radioimmunotherapybased autologous transplant trial Medical condition would contraindicate allogeneic transplantation Evidence Human AntiMouse Antibody ( HAMA ) patient prior exposure therapeutic murine antibody Eligible therapeutic option likely better longterm diseasefree survival lower potential toxicity ( e.g. , nontransplant therapy , autologous transplant , etc . ) study Other grave medical condition consider represent contraindication bone marrow transplant ( BMT ) ( e.g . unstable angina , pulmonary dysfunction [ diffuse capacity lung carbon monoxide ( DLCO ) &lt; 30 % , total lung capacity ( TLC ) &lt; 30 % , continuous supplemental oxygen ] , acquire immune deficiency syndrome [ AIDS ] , etc . ) DONOR : Identical twin DONOR : Age le 12 year DONOR : Pregnancy DONOR : Infection HIV DONOR : Inability achieve adequate venous access DONOR : Known allergy GCSF DONOR : Current serious systemic illness infection</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2016</verification_date>
</DOC>